AAAAAA
Results:
1-10
|
Results: 10
Authors:
Euller-Ziegler, L
Velicitat, P
Bluhmki, E
Turck, D
Scheuerer, S
Combe, B
Citation: L. Euller-ziegler et al., Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration, INFLAMM RES, 50, 2001, pp. S5-S9
Authors:
Combe, B
Velicitat, P
Garzon, N
Bluhmki, E
Citation: B. Combe et al., Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients, INFLAMM RES, 50, 2001, pp. S10-S16
Authors:
Stingele, R
Bluhmki, E
Hacke, W
Citation: R. Stingele et al., Bootstrap statistics of ECASS II data: Just another post hoc analysis of anegative stroke trial?, CEREB DIS, 11(1), 2001, pp. 30-33
Authors:
Lesaffre, E
Bluhmki, E
Wang-Clow, F
Berioli, S
Danays, T
Fox, NL
Van de Werf, F
Citation: E. Lesaffre et al., The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction, EUR HEART J, 22(11), 2001, pp. 898-902
Authors:
Berger, C
Fiorelli, M
Steiner, T
Schabitz, WR
Bozzao, L
Bluhmki, E
Hacke, W
von Kummer, R
Citation: C. Berger et al., Hemorrhagic transformation of ischemic brain tissue - Asymptomatic or symptomatic?, STROKE, 32(6), 2001, pp. 1330-1335
Authors:
Larrue, V
von Kummer, R
Muller, A
Bluhmki, E
Citation: V. Larrue et al., Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator - A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II), STROKE, 32(2), 2001, pp. 438-441
Authors:
Wang-Clow, F
Lynn, N
Cannon, CP
Gibson, M
Berioli, S
Bluhmki, E
Danays, T
Braunwald, E
Van De Werf, F
Stump, DC
Citation: F. Wang-clow et al., Determination of a weight-adjusted dose of TNK-tissue plasminogen activator, AM HEART J, 141(1), 2001, pp. 33-40
Authors:
Bluhmki, E
Windeler, J
Hacke, W
Citation: E. Bluhmki et al., Neurological scales as endpoints in stroke studies. Aspects of statisticalanalysis, NERVENARZT, 71(10), 2000, pp. 797-801
Authors:
Van de Werf, F
Adgey, J
Ardissino, D
Armstrong, PW
Aylward, P
Barbash, G
Betriu, A
Binbrek, AS
Califf, R
Diaz, R
Fanebust, R
Fox, K
Granger, C
Heikkila, J
Husted, S
Jansky, P
Langer, A
Lupi, E
Maseri, A
Meyer, J
Mlczoch, J
Mocceti, D
Myburgh, D
Oto, A
Paolasso, E
Pehrsson, K
Seabra-Gomes, R
Soares-Piegas, L
Sugrue, D
Tendera, M
Topol, E
Toutouzas, P
Vahanian, A
Verheugt, F
Wallentin, L
White, H
Berioli, S
Bluhmki, E
Brower, R
Danays, T
Fox, NL
Girault, C
Goetz, G
Houbracken, K
Jakob, H
Kaye, J
Sarelin, H
Clow, FW
Hacke, W
von Kummer, L
Lesaffre, E
Bluhmki, E
Bogaerts, K
Munster, K
Scheys, I
Truyen, M
Clow, FW
Fox, KAA
Brower, R
Hallstrom, A
Jones, D
Maggioni, A
Weaver, D
Citation: F. Van De Werf et al., Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial, LANCET, 354(9180), 1999, pp. 716-722
Authors:
Van de Werf, F
Cannon, CP
Luyten, A
Houbracken, K
McCabe, CH
Berioli, S
Bluhmki, E
Sarelin, H
Wang-Clow, F
Fox, NL
Braunwald, E
Citation: F. Van De Werf et al., Safety assessment of single-bolus administration of TNK tissue-plasminogenactivator in acute myocardial infarction: The ASSENT-1 trial, AM HEART J, 137(5), 1999, pp. 786-791
Risultati:
1-10
|